<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173003</url>
  </required_header>
  <id_info>
    <org_study_id>1.1.7</org_study_id>
    <nct_id>NCT01173003</nct_id>
  </id_info>
  <brief_title>Expansion Study of a Simplified Regimen of Medical Abortion Thru 63 Last Menstrual Period (LMP) in Tunisia</brief_title>
  <official_title>An Open Label Study of 400 mcg Sublingual Misoprostol Following Mifepristone 200 mg for Abortion up to 63 Days LMP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Formation et de la Recherche, Tunisia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <brief_summary>
    <textblock>
      This open-label study is being conducted to determine whether national expansion of a 400 mcg
      of sublingual misoprostol (i.e., under the tongue) taken 24 hours following administration of
      mifepristone 200 mg is effective and acceptable to new abortion providers in 14 regions.

      The goal of this study is to provide answers to the following four questions:

        1. What is the effectiveness of this regimen of medical abortion with mifepristone followed
           by 400 mcg sublingual misoprostol up to 63 days since the last menstrual period (LMP)?

        2. Are the side effects with sublingual use tolerable for women?

        3. Is sublingual administration of misoprostol acceptable to women?

        4. Are women satisfied with counseling and services received in new centers offering
           medical abortion?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for surgical completion for incomplete abortions or ongoing viable pregnancies at follow up visit Study day 15.</measure>
    <time_frame>2 weeks after mifepristone administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability for women</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">688</enrollment>
  <condition>Induced Abortion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone, misoprostol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women presenting for medical abortion who consent to participate

          -  Possibility of final gestational age of less than or equal to 63 days

          -  General good health

          -  Willing to provide contact information for purposes of follow-up

        Exclusion Criteria:

          -  Conditions which contraindicate the use of mifepristone or misoprostol

          -  Women presenting for medical abortion who do not consent to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasha Dabash, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Selma Hajri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive Health Consultant</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mongia Ben Attia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Office Nationale de la Famille et de la Population</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N Gueddana, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ONFP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatma Temimi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ONFP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Hassairi</last_name>
    <role>Principal Investigator</role>
    <affiliation>ONFP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centres (14) de Planification Familiale de L'ONFP</name>
      <address>
        <city>Tunis</city>
        <state>Various</state>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2010</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medical abortion</keyword>
  <keyword>mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <keyword>Tunisia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

